Pierot and colleagues reported that 20 patients with 21 aneurysms were treated by using the Web in three European centres. The team made a note of successful deployment of the Web, immediate post-treatment angiographic results, adverse events, clinical outcome, and angiographic follow-up results.
The majority of aneurysms were located in the middle cerebral artery (8/21, 38.1%). Five were located on the anterior communicating artery (23.8%), and four (19.1%) each on the basilar artery and internal carotid artery.
The investigators did not report any treatment failures. Over 75% of patients were treated exclusively with the Web device. The other patients required additional coiling and/or stent placement. The team noted that one patient (4.8%) experienced transient clinical worsening (mRS 1 at one month and mRS 0 at three months) related to a thromboembolic event. They noted a detachment of the Web device which was subsequently retrieved without adverse effects.
Pierot told LINNC delegates that short-term follow-up (2–8 months) had revealed total occlusion or neck remnant in 80% of aneurysms.
At LINNC 2012, Boris Lubicz, Hôpital Erasme, Brussels, Belgium also presented his as-yet unpublished initial clinical experience with the Web for treatment of twenty-one wide neck unruptured bifurcation aneurysms, which represents that largest single centre experience to date.
Sequent Medical told NeuroNews that the company intends to continue with a controlled, gradual introduction of the Web at centres in Europe. The company is also initiating a number of Europe-based clinical studies in order to collect formal multicentre clinical data.
